Product Overview
p21 ( C - term ) peptide ( human )
Tag/Conjugate
Unconjugated
Buffer
PBS with 100ug BSA 0.1% sodium azide
Preservative
0.1% Sodium Azide
Storage
Keep as concentrated solution, aliquot and store at 4°C.
Antigen Description
This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene. [provided by RefSeq, Nov 2010]
Function
cyclin binding; cyclin-dependent protein kinase activating kinase activity; cyclin-dependent protein serine/threonine kinase inhibitor activity; metal ion binding; protein binding; protein complex binding;
Synonyms
CDKN1A; cyclin-dependent kinase inhibitor 1A (p21, Cip1); P21; CIP1; SDI1; WAF1; CAP20; CDKN1; MDA-6; p21CIP1; cyclin-dependent kinase inhibitor 1; DNA synthesis inhibitor; CDK-interacting protein 1; CDK-interaction protein 1; wild-type p53-activated fragment 1; melanoma differentiation associated protein 6;
Citations
Have you cited CDBP2160 in a publication?
Let us know and earn a reward for your research.
Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
Liedberg, F; Anderson, H; et al. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: Much effort to no avail. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 26:17-24(2008).
Lotan, Y; Bagrodia, A; et al. Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. EUROPEAN UROLOGY 64:465-471(2013).